start portlet menu bar end portlet menu bar

RHINISENG®: Efficacy of the basic vaccination scheme (vaccination and revaccination) and the booster vaccination

Strona główna Wiedza RHINISENG®: Efficacy of the basic vaccination scheme (vaccination and revaccination) and the booster vaccination

RHINISENG®: Efficacy of the basic vaccination scheme (vaccination and revaccination) and the booster vaccination

RHINISENG® is a vaccine against progressive (PAR) and non-progressive atrophic rhinitis (NPAR) indicated for pregnant sows and gilts to passively protect their offspring. The RHINISENG® recommended vaccination scheme includes a basic vaccination scheme (vaccination 8-6 weeks before farrowing and revaccination 4-3 weeks before farrowing) and a booster dose (4-3 weeks before the subsequent farrowing). This study evaluated the vaccine pre-clinical efficacy and the duration of immunity for active immunization of the sows.

Pobierz ten artykuł

1 MB

O tym artykule

Autorzy

Montané, J.; Monells, M.; Ruiz, M.C.; Roca, M.; Camprodon, A.; March, R.; Sitjà, M.

Streszczenie

RHINISENG® significantly reduced the atrophic rhinitis lesions reproduced in a severe experimental infection, both after applying the basic vaccination scheme and after boosting during the subsequent gestation (Figure 1), even when sows where vaccinated at the maximum interval recommended between the basic vaccination scheme and parturition, i.e. 8 and 4 weeks before farrowing.

Powiązane usługi

HIPRA Diagnos

Powiązane produkty

RHINISENG®

Powiązane publikacje

Reduction of nasal lesions and production losses after vaccination against non-progressive atrophic rhinitis Efficacy of a novel vaccine in an atrophic rhinitis-infected farm Case report: improving piglets growth performance coming from vaccinated sows with RHINISENG® in China

Udostępnij na

start portlet menu bar

RHINISENG®: Efficacy of the basic vaccination scheme (vaccination and revaccination) and the booster vaccination

Display portlet menu
end portlet menu bar

Patrz także

Publikacje

Immunocrit assay is a tool to evaluate the management of maternally derived immunity in so...

26-06-2019
Streszczenia choroby

Edema disease

03-11-2017
Aktualności

Third theoretical and practical HIPRA UNIVERSITY course on Newcastle disease

25-06-2019